ReviewJournal of ophthalmic & vision research
Systemic Immunomodulatory Strategies in High-risk Corneal Transplantation.
Review in Journal of ophthalmic & vision research. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed.
- Predictors of Postoperative Corneal Clarity After Corneal Reconstruction for Deep Corneal Ulcers and Perforations in Dogs.Veterinary ophthalmology · 2026Article
- Indications and long-term outcomes of repeat optical penetrating keratoplasty.Indian journal of ophthalmology · 2026Article
- Article
- Etiology, surgical management, and outcomes of patients with scleral thinning.The Journal of international medical research · 2026Observational
- Differential Effects of T-Cell Inhibitors and Antimetabolites on Graft Survival in High-Risk Penetrating Keratoplasty: A Tertiary Center Experience.Ophthalmology science · 2026Article
- Long-Term Graft Survival and Visual Outcomes in Deep Anterior Lamellar Keratoplasty (DALK): A Narrative Review.Journal of ophthalmology · 2026Review
- IL-6 amplifies corneal transplant alloimmunity by inducing dysfunctional IFN-γ- secreting Treg through the VEGFA-VEGFR1 axis.Transplant immunology · 2025Article
- Mobile health and postoperative self-care following glaucoma, cataract, or corneal transplant surgeries.BMC ophthalmology · 2025Article
- Reconstruction of deep and perforating corneal defects in dogs-A review (Part I/III): Autogenous ocular tissues, donor tissues, and corneal clarity scoring.Veterinary ophthalmology · 2025Review
- A chimeric anti-vascularization immunomodulator prevents high-risk corneal transplantation rejection via ex vivo gene therapy.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- Acquired immunostimulatory phenotype of migratory CD103+ DCs promotes alloimmunity following corneal transplantation.JCI insight · 2024Article
- Preparation, physico-biochemical characterization, and proteomic analysis of highly transparent corneal extracellular matrices for lamellar keratoplasty and tissue-engineered cornea construction.Materials today. Bio · 2024Article
- Review
- Myeloid-derived suppressor cells promote allograft survival by suppressing regulatory T cell dysfunction in high-risk corneal transplantation.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2024Article
- Retinal transplant immunology and advancements.Stem cell reports · 2024Review
- Efficacy of mycophenolate mofetil combined with topical 0.05% tacrolimus in high-risk keratoplasty: 1-year cohort study.International journal of ophthalmology · 2024Article
- NF-κB c-Rel Is a Potential Therapeutic Target for Acute Corneal Transplant Rejection.Investigative ophthalmology & visual science · 2023Article
- Six-month effective treatment of corneal graft rejection.Science advances · 2023Article
- Outcomes following tacrolimus systemic immunosuppression for penetrating keratoplasty in infants and young children.Eye (London, England) · 2022Article
- Management and Treatment Outcomes of High-Risk Corneal Transplantations.Journal of clinical medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cornea is the most commonly transplanted tissue in the body. Although corneal grafts generally have high success rates, transplantation onto inflamed and vascularized host beds, or so-called high-risk corneal transplantation, has a high rate of graft rejection. The management of this high-risk corneal transplantation is challenging and involves numerous measures. One of the key measures to prevent graft rejection in these cases is the use of systemic immunosuppressive agents. In this article, we will review the systemic immunosuppressive agents most commonly used for high-risk corneal transplantation, which include corticosteroids, cysclosporine A, tacrolimus, mycophenolate mofetil, and rapamycin. Benefits, risks, and published data on the use of these medications for high-risk corneal transplantation will be detailed. We will also summarize novel immunoregulatory approaches that may be used to prevent graft rejection in high-risk corneal transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.